Optimum Strategic Communications’ Post

𝗕��𝗰𝘁𝗲𝗿𝗶𝗼𝗽𝗵𝗮𝗴𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 𝗠𝗮𝗿𝗸𝗲𝘁 𝟮𝟬𝟮𝟰-𝟮𝟬𝟯𝟬. 𝗚𝗹𝗼𝗯𝗮𝗹 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗥𝗲𝗽𝗼𝗿𝘁 𝗧𝗼 𝗞𝗻𝗼𝘄 𝗖𝘂𝗿𝗿𝗲𝗻𝘁 𝗮𝗻𝗱 𝗙𝘂𝘁𝘂𝗿𝗲 𝗗𝗲𝗺𝗮𝗻𝗱. 𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗳𝗼𝗿 𝗦𝗮𝗺𝗽𝗹𝗲 𝗣𝗗𝗙: https://lnkd.in/ddnWHwXE Phages, formally known as bacteriophages, are viruses that specifically target and kill bacteria, proving effective even against multi-drug resistant strains when antibiotics fail, thus potentially saving lives from severe infections. These entities, the most common in nature, hold significant promise across human medicine, dentistry, veterinary science, and agriculture. The report provides an overview of the Bacteriophage Therapy industry's development, market status for applications in organ transplantation and bacterial infections (both oral and topical), and profiles key enterprises in both developed and developing markets. It also analyzes cutting-edge technologies, patents, applications, and market trends. Regionally, North America and Europe show steady growth due to government initiatives and increasing consumer awareness, while Asia-Pacific, particularly China, leads the market driven by strong domestic demand, supportive policies, and a robust manufacturing base. The report offers a comprehensive view of the industry, detailing market dynamics, trends, challenges, and opportunities. *𝗕𝘆 𝗧𝘆𝗽𝗲: Oral, Topical, Parenteral *𝗕𝘆 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: Organ Transplantation, Bacterial Infections, Alcoholic Hepatitis, Other *𝗕𝘆 𝗥𝗲𝗴𝗶𝗼𝗻: North America, Europe, Asia-Pacific, South America, Middle East & Africa *𝗕𝘆 𝗞𝗲𝘆 𝗣𝗹𝗮𝘆𝗲𝗿𝘀: Armata Pharmaceuticals, Inc., Pherecydes Pharma, INTRALYTIX, INC., Phagelux Agrihealth Inc., InnoPhage, Lda., Locus Biosciences, Inc., TechnoPhage, SA, Eligo Bioscience, BioNTech R&D (Austria) GmbH, PhagePro, Adaptive Phage Therapeutics, INTODEWORLD, INC., BiomX Inc, Phi Therapeutics, Inc., ContraFect Corp #BacteriophageTherapy #PhageTherapy #AntibioticResistance #Superbugs #PhageScience #PhageResearch #InfectiousDisease #PhageVsBacteria #Microbiome #Biotechnology #MedicalInnovation #FutureOfMedicine #PhageTreatment #HealthcareRevolution #PhageMedicine

Several people asked me to give an opinion on this so here we go. Yes, like in any high-profile science area there are “myths and misconceptions” in the (gut) #microbiome field. Proliferation of these and hyping don’t serve the field. It’s good that the authors Alan Walker and Lesley Hoyles are calling this out, but at the same time several seem indeed quite trivial to me (ex: nr of cells per gram feces; 1 to 2kg of total biomass or less; outnumbering human cells…). For these as well as others, they have been largely debunked for a while now and no longer form part of commonly accepted “facts” (ex: Firmicutes:Bacteroidetes ratio in obesity; sequencing is unbiased; gut bugs are uncultivatable). I also think their nuancing regarding functional redundancy should be appreciated. Similarly, the focus on fully standardized technologies is often overshooting. In human therapeutics development they are often supportive and rarely a clinical endpoint (We don’t treat a microbiome but a patient!). Methodologies serving their purpose and validated. But most importantly, this should not draw attention away from where our focus should really be. The last two decades have provided a wealth of data which should make us all very excited about the therapeutic potential of the human microbiome in immune-drive and infectious disease across body sites. Almost any immunological target may benefit from a microbiome (co)therapy. With two approved drugs on the market, now is the time for scientists, drug developers and investors to accelerate efforts and deliver on the opportunity. #microbiota #drugdevelopment #immunotherapy https://lnkd.in/ep9aW9uy

🧬The science community has been haunted by the antimicrobial resistance crisis. 💡While looking for solutions, Synmedix, a biotechnology company, created novel antibacterial therapies to address the antimicrobial crisis. 👉Founded in Dr. Eric Brown's lab at McMaster University, CEO Dr. Maya Farha discovered that a buffering agent can be leveraged to improve antibiotic performance. 🙌Starting their journey at Innovation Factory, Synmedix took part in iF’s Synapse Life Science Pitch Competition and #SOPHIE program, and is now set to enter the commercialization stage! 🧪Read the full story to learn more about how Symedix is going to reshape the future of antibiotics here: https://ow.ly/76ry50QGJN5 #AMR #Antibiotics #SOPHIE #SynapseCompetition #Technology #Innovation #Biotechnology #LifeSciences #HealthTech #Ontario

Will phage therapy dethrone antibiotics? As the antibiotics market is projected to surpass $71.05 billion by 2032, the biotech and pharma sectors face a daunting challenge: investing billions of dollars and decades in antibiotics development, only for bacteria to rapidly develop resistance, a phenomenon known as antimicrobial resistance (AMR). This resistance can emerge shortly after a new antibiotic hits the market, undermining financial returns and public health efforts. The World Health Organization has labeled AMR a significant threat, with 1.3 million deaths attributed to it in 2022 alone. This financial and efficacy dilemma is pushing the industry towards bacteriophage therapy, which uses viruses to selectively target bacteria. Bacteriophages, often just called phages, are like nature's own precision-guided missiles against bacteria. They can infect and destroy specific bacteria without harming the cells of the organism they're helping, bypassing the issue of resistance. Key players like BiomX Inc, Cytophage Technologies Inc., DotBio, Adaptive Phage Therapeutics, Armata Pharmaceuticals, Inc., Eligo Bioscience, INTRALYTIX, INC., and Locus Biosciences, Inc. are leading the charge, exploring phage therapy as a potential replacement for traditional antibiotics. #biotechbriefing #biotechnews

𝐏𝐡𝐚𝐠𝐞 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝟐𝟎𝟐𝟒-𝟐𝟎𝟑𝟏. 𝐆𝐥𝐨𝐛𝐚𝐥 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭 Phage therapy utilizes bacteriophages, viruses that selectively infect and destroy bacteria, as a targeted therapeutic approach for bacterial infections. These viruses exhibit high specificity towards particular bacterial strains, enabling precise targeting by interacting with specific receptors on the bacterial surface. This specificity ensures the elimination of pathogenic bacteria without harming beneficial bacteria or human cells. Particularly effective against bacterial biofilms, which pose challenges for traditional antibiotics, phage therapy demonstrates promise in disrupting these complex structures. The Phage Therapy Technology market report offers a comprehensive analysis of global market dynamics, including size, regional variations, segmentation, competitive landscape, regulatory impacts, recent developments, and growth opportunities. With insights into product launches, technological innovations, and strategic growth analysis, businesses can leverage this information to tap into specialized markets for expansion. 𝐓𝐨 𝐊𝐧𝐨𝐰-𝐓𝐡𝐞 𝐆𝐥𝐨𝐛𝐚𝐥 𝐒𝐢𝐳𝐞 𝐀𝐧𝐝 𝐃𝐞𝐦𝐚𝐧𝐝 𝐎𝐟 𝐓𝐡𝐞 𝐏𝐡𝐚𝐠𝐞 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲.𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗳𝗼𝗿 𝗦𝗮𝗺𝗽𝗹𝗲 𝗣𝗗𝗙: https://lnkd.in/d9nbCAT7 *𝗕𝘆 𝗧𝘆𝗽𝗲, 𝐜𝐨𝐯𝐞𝐫𝐬 : *𝗕𝘆 𝐄𝐧𝐝 𝐔𝐬𝐞𝐫𝐬- for Human, for Animals, for Plants *𝗕𝘆 𝐆𝐞𝐧𝐨𝐦𝐞- DsDNA Bacteriophage, SsDNA Bacteriophage, DsRNA Bacteriophage, SsRNA Bacteriophage *𝗕𝘆 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻, 𝐜𝐚𝐧 𝐛𝐞 𝐝𝐢𝐯𝐢𝐝𝐞𝐝 𝐢𝐧𝐭𝐨: Medical, Food Industry, Agriculture, Others *𝗕𝘆 𝗥𝗲𝗴𝗶𝗼𝗻𝘀:  North America, Europe, Asia-Pacific, South America, Middle East & Africa *𝗕𝘆 𝗞𝗲𝘆 𝗣𝗹𝗮𝘆𝗲𝗿𝘀: Vésale Bioscience, Adaptive Phage Therapeutics, Proteon Pharmaceuticals, PHIOGEN, Phageguard, Armata Pharmaceuticals, Inc., SyntBioLab Inc., Antibody Analytics, APS Biocontrol Ltd., BiomX Inc, EcoPhage, INTRALYTIX, INC. Locus Biosciences, Inc., Micreos , Omnilytics Inc #phagetherapy #bacteriophages #antibioticalternatives #precisionmedicine #biofilmresistance #marketanalysis #globalhealth #healthcareinnovation #infectiousdiseases #biotechindustry #therapeuticapproach #medicalresearch #microbiomebalance #healthtech #innovativetreatments #biomedical #healthcarestrategy #regulatorylandscape #growthopportunities #technologyadvancements

New pubblication! 📚 The development of media for cell culture is a major issue in the biopharmaceutical industry, for the production of therapeutics, immune-modulating molecules and protein antigens. Chemically defined media offer several advantages, as they are free of animal-derived components and guarantee high purity and a consistency in their composition. Microorganisms of the genus Leishmania represent a promising cellular platform for production of recombinant proteins, but their maintenance requires supplements of animal origin, such as hemin and fetal bovine serum. In the present study, three chemically defined media were assayed for culturing Leishmania tarentolae, using both a wild-type strain and a strain engineered to produce a viral antigen. Among the three media, Schneider's Drosophila Medium supplemented with Horseradish Peroxidase proved to be effective for the maintenance of L. tarentolae promastigotes, also allowing the heterologous protein production by the engineered strain. Finally, the engineered strain was maintained in culture up to the 12th week without antibiotic, revealing its capability to produce the recombinant protein in the absence of selective pressure. https://lnkd.in/d5B752Ae

Antibiotic resistance is on the rise because of misuse of broad-spectrum antibiotics. At Resistell, we are poised to revolutionize antibiotic prescriptions. Thank you, Hillary Sanctuary, for writing about my personal experience with AMR and sharing it in the EPFL News: https://lnkd.in/de-yRq45 #Resistell #infectiousdiseases #AMR #AntibioticResistance #antimicrobialresistance #antibiogram #AST #antibiotic #antimicrobials #diagnostics #medtech #healthcare #healthtech #health #clinics #innovation #healthcareinnovation #biotech #lifescience #research #swissstartups #TOP100SSU #TOP100 #venturekick #venturelab #eicaccelerator #chuv #occident #epfl #spinoff #startup

Introducing Biotech Dodo, the one-minute biotech roundup! 🦤 It’s been a tough few centuries, but Dodo is back and ready to serve the – piping hot – biotech tea! Whether you’re already in the biotech space, or are simply bio-curious, Biotech Dodo is your weekly highlight reel of the best news, podcast recommendations, jobs and events in the sector – all readable in the time it takes to boil the kettle!   Read issue #1, and subscribe/follow today!👇 #biotech #healthtech #healthcare #digitalhealth #marketing

Chronic Wounds Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | Paracrine, Inc, Oneness Biotech, MediWound, PolarityTE #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech

𝐍𝐨𝐯𝐞𝐥 𝐬𝐞𝐫𝐢𝐞𝐬 𝐨𝐧 #𝐈𝐕𝐈𝐕𝐂 𝐨𝐟 𝐏𝐫𝐨𝐃𝐢𝐠𝐞𝐬𝐭’𝐬 𝐭𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦𝐬 All of ProDigest’s in vitro technology platforms for the simulation of the gut and its microbiome deliver excellent predictability of the in vivo outcome. Apart from providing insights into #MoA funneling of the development pipeline and ultimately de-risking clinical trials, it serves as an excellent alternative to #animaltesting This series summarizes case studies covering all our different technologies ranging from highly complex dynamic models to high throughput screening approaches with a wide range of product types #probiotic #prebiotic, #postbiotic #synbiotic #microbiome #foodingredients #nutraceuticals #API #fomulations #guthealth  #animalhealth ... for a variety of population groups and diseases states. Reach out to Massimo Marzorati , Dora Akritidou , Peter B. Azmi or Bart Roucourt if you want to learn more about our services and discuss how it can transform your research.